IMD has published a commentary titled "Corporate innovation strategy: Self-disrupt or fall behind," framing internal cannibalization as a non-optional discipline for incumbent R&D organizations.

The piece, distributed via the institute's editorial channels, joins a sustained body of management commentary urging R&D leaders to treat self-cannibalization as a portfolio discipline rather than a contingency exercise. The article's title positions the question as binary, presenting self-disruption as the alternative to gradual erosion of market position.

What does "self-disruption" demand of R&D managers?

Self-disruption refers to deliberate investment by an incumbent in technologies, business models or product architectures that compete with the company's own revenue base. The mechanism differs from ordinary renewal: the new offering is engineered to draw customers away from the firm's existing lines, accelerating depreciation of installed technology and shortening the useful horizon of assets already on the books.

For R&D managers, the operational implications sit at the capital-allocation layer. Budget systems that reward revenue extension from established platforms tend to underfund internal substitutes. Stage-gate criteria optimized for incremental improvement filter out projects whose commercial success depends on displacing the company's own SKUs.

How does this reshape lab workflow?

Self-disruption projects need ring-fenced budgets because they compete poorly in shared allocations against lines that protect incumbency. They also demand portfolio-level review at shorter cadence than annual planning cycles permit.

Lab workflow consequences include physically and organizationally separating self-disruption teams from the units whose products they aim to replace. Co-location with the incumbents they will erode tends to produce mission drift, with teams defaulting to compatibility rather than displacement. Performance metrics tied to short-term margins penalize teams whose deliverable is obsolescence of a high-margin legacy line.

What does the IMD piece itself add?

IMD's commentary is positioned as a strategic directive rather than a primary-research article. The title implies a normative claim addressed to executives and boards, not a new empirical study. R&D managers seeking measured evidence on self-disruption outcomes — patent-share trajectories, R&D intensity ratios, time-to-cannibalization — must follow the citation chain into the underlying management literature rather than rely on the headline thesis.

The institute's editorial decision to frame the question in binary terms pushes the argument into prescription. Few corporate R&D organizations face a true either-or choice; the operational reality is a portfolio of bets at different displacement stages, balanced against the cash flow needed to fund them. A board-level framing that reduces the decision to a slogan can distort capital-allocation discussions.

What should R&D portfolio leads take from it?

The value of the IMD framing lies less in the prescription than in the framing itself. A committee that hears "self-disrupt or fall behind" should respond with questions about the pipelines under threat, the budget mechanism that funds their displacement, and the KPIs that measure cannibalization rate. Without those controls, the phrase licenses additional R&D spend without specifying operational targets.

IMD's contribution here is to restate, in compact form, a question R&D leaders have worked through for two decades: which internal projects justify cannibalization of existing revenue, and which should sunset through normal competition. The forward signal for R&D managers is whether governance reviews in their own organizations now apply that question explicitly, or continue to defer it under stage-gate inertia.